S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:SCYX

SCYNEXIS Stock Forecast, Price & News

$4.80
+0.05 (+1.05%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.61
$4.92
50-Day Range
$4.75
$7.69
52-Week Range
$4.21
$10.25
Volume
173,323 shs
Average Volume
279,408 shs
Market Capitalization
$114.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.95
30 days | 90 days | 365 days | Advanced Chart
Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.


SCYNEXIS logo

About SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
Employees
38
Year Founded
N/A

Sales & Book Value

Annual Sales
$120 thousand
Book Value
$1.16 per share

Profitability

Net Income
$-55.19 million
Pretax Margin
-393.33%

Debt

Price-To-Earnings

Miscellaneous

Free Float
23,112,000
Market Cap
$114.96 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/25/2022
Next Earnings (Estimated)
4/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

634th out of 1,416 stocks

Pharmaceutical Preparations Industry

302nd out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS
or view top-rated stocks.

How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SCYX shares have decreased by 38.5% and is now trading at $4.80.
View which stocks have been most impacted by COVID-19
.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for SCYNEXIS
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) announced its earnings results on Wednesday, November, 10th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.73. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.50 million. During the same quarter last year, the firm posted ($0.28) earnings per share.
View SCYNEXIS's earnings history
.

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

SCYNEXIS's stock reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

4 brokers have issued twelve-month target prices for SCYNEXIS's shares. Their forecasts range from $20.00 to $35.00. On average, they expect SCYNEXIS's share price to reach $25.67 in the next twelve months. This suggests a possible upside of 434.7% from the stock's current price.
View analysts' price targets for SCYNEXIS
or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Marco Taglietti, President, Chief Executive Officer & Director
  • Lawrence R. Hoffman, Chief Financial Officer
  • David Angulo Gonzalez, Chief Medical Officer
  • Rajeshwar Motheram, SVP-Pharmaceutical Development & Supply Chain
  • Nkechi Azie, VP-Clinical Development & Medical Affairs

What other stocks do shareholders of SCYNEXIS own?

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $4.80.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $114.96 million and generates $120 thousand in revenue each year. The company earns $-55.19 million in net income (profit) each year or ($4.43) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 38 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

Where are SCYNEXIS's headquarters?

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at (201) 884-5485, via email at [email protected], or via fax at 201-884-5490.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.